Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | EPHA2 | P29317 | 5/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.42 |
| ▸ | VDR | P11473 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20374727 | 1.00 | RORC (0.47) | RORCEPHA2GPBAR1HSD17B10TDP1 | |
| SCHEMBL20370380 | 0.81 | RORC (0.46) | RORCEPHA2GPBAR1HSD17B10TDP1 | |
| SCHEMBL20374527 | 0.81 | RORC (0.46) | RORCEPHA2GPBAR1HSD17B10TDP1 | |
| SCHEMBL19197390 | 0.80 | USP2 (0.52) | RORCEPHA2GPBAR1HSD17B10TDP1 | |
| SCHEMBL10017480 | 0.78 | RORC (0.52) | RORCEPHA2GPBAR1HSD17B10TDP1 | |
| SCHEMBL12577480 | 0.78 | RORC (0.51) | RORCEPHA2GPBAR1HSD17B10TDP1 | |
| SCHEMBL21298975 | 0.77 | RORC (0.45) | RORCEPHA2GPBAR1HSD17B10TDP1 | |
| SCHEMBL19755054 | 0.77 | RORC (0.45) | RORCEPHA2GPBAR1HSD17B10TDP1 | |
| SCHEMBL30094040 | 0.74 | GPBAR1 (0.69) | RORCEPHA2GPBAR1HSD17B10TDP1 | |
| SCHEMBL12577477 | 0.73 | RORC (0.46) | RORCEPHA2GPBAR1HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214615-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT | JNC CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| US-10662379-B2 | Polymerizable polar compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2020-05-26 | — | — | US | disclosed |
| US-20180195005-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180195005-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180195005-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, MBD2, PAXBP1 | RORC 1292/4885EPHA2 1249/4885GPBAR1 2519/4885 |
| US-10662379-B2 | Polymerizable polar compound, liquid crystal composition and liquid crystal display device | SP1, MBD2, PAXBP1 | RORC 1292/4885EPHA2 1249/4885GPBAR1 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.